Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism

Abstract

Abstract: Objective To investigate the effect of FNDC5 on hepatocellular carcinoma (HCC) and its related mechanisms in order to propose new ideas for the treatment of HCC.Methods HepG2 cells were divided into four groups based on FNDC5 concentration (0, 5, 10 and 20 μM). The activity, invasion and migration of HepG2 cells,as well as apoptosis rate, were analyzed by MTT test, colony formation test, Transwell test, flow cytometry and cell scratch test. The impact of FNDC5 on the Wnt/β-catenin pathway was analyzed by Western blot.Results FNDC5 reduced the growth activity of HepG2 cells (92.86±0.32 vs 79.32±0.17 vs 50.11±0.56 vs 29.29±0.96), inhibited HepG2 cell colony formation (238.25±12.28 vs 126.91±9.56 vs 68.93±9.25 vs 32.53±7.32), and prevented the occurrence of HepG2 cell invasion and migration (87.13±2.18 vs 66.23±2.16 vs 46.23±3.27 vs 22.56±5.12; 88.46±12.55 vs 55.08±9.21 vs 39.62±5.63 vs 19.26±5.71).FNDC5 also induced apoptosis in HepG2 cells (1.46±0.23 vs 5.08±0.11 vs 9.66±0.23 vs 13.27±1.01).Conclusion HepG2 cell metastatic activity can be inhibited by FNDC5, and the anti-tumor effect of FNDC5 may be connected to the Wnt/β-catenin signal pathway.

Key words: fibronectin type III domain containing 5, HepG2, Transfer activity, Hepatocellular carcinoma

YUAN Qing-gong, ZHANG Yan, LI Jun-hui, YANG Wen-bin. Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism[J]. Chinese Hepatolgy, 2023, 28(8): 943-946.

References

[1] 孟金霞,卢喜玲,别文倩,等. 乙肝肝硬化并发原发性肝癌的相关危险因素分析. 实用癌症杂志,2022,37(5):777-779.
[2] 刘振宇,黄秀婷,田晓娟,等. Wnt/β-Catenin信号通路对氧化应激损伤促进食管癌细胞凋亡的调控研究. 广州医科大学学报,2019,47(5):1-4.
[3] Tejeda ME, Canto P, Tenorio-Torres A, et al. Increased FNDC5/IRISIN protein expression in breast cancer tissue is associated with obesity in postmenopausal women. J Clin Pathol, 2021, 15(2):2471-2476.
[4] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019,16(10):589-604.
[5] Kulik L, El-serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019,156(2):477-491.
[6] Ma LA, Kim H, Desbordes C. Effects of biguanides on growth and glycolysis of bladder and colon cancer cells. Anticancer Res, 2018,38(9):5003-5011.
[7] Zhu T, Zhang W, Zhang Y, et al. Irisin/FNDC5 inhibits the epithelial-mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathway. Arch Gynecol Obstet, 2022,306(3):841-850.
[8] Zhang Y, Li C, Hu C, et al. Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1. EMB O Rep, 2019, 20(10):e48115.
[9] Hao Q, Li T, Zhang X, et al. Expression and roles of fatty acid synthase in hepatocellular carcinoma. Oncol Rep, 2014,32(6):2471-2476.
[10] Wang X, Mao L, Li C, et al. The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. Expert Rev Mol Med, 2022,2(4):16-23.
[11] Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol, 2020,13(1):165-173.
[12] Yu F, Yu C, Li F, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther, 2021,6(1):307-316.
[13] Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther, 2022,7(1):3-11.
[14] Anthony CC, Robbins DJ, Ahmed Y, et al. Nuclear regulation of Wnt/β-Catenin signaling: it's a complex situation. Genes (Basel), 2020,11(8):886-897.

[1]	NIE Bin, ZHAO Tie-jun, ZHANG Sheng-long. A prognostic analysis on the radical resection of primary hepatocellular carcinoma with microvascular invasion by different resection margin schemes [J]. Chinese Hepatolgy, 2023, 28(8): 921-923.
[2]	HU Zhi-qiang, MEN Fen-yong, LIU Dong. A correlation analysis between immune-related adverse events and the curative effect caused by immune checkpoint inhibitors on patients with advanced primary Hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 935-937.
[3]	XU Jia-pin, SHAO Chun-yan, LIU Di-fa, XU Ya-chun. The value of diffusion weighted imaging of voxel incoherent motion in predicting microvascular invasion and evaluating the efficacy of TACE therapy on hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 938-942.
[4]	HUANG Qian, LI Ya-nan, ZENG Da-wu. Expression and prognostic value of ANLN, CYP2C9 and HMMR in hepatitis B virus-associated hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 775-780.
[5]	LI Gang, CAO Zhi-qun, NIU Shuai. Effect of TACE on serum tumor markers and recurrence risk after radical hepatocellular carcinoma resection at different time [J]. Chinese Hepatolgy, 2023, 28(7): 781-784.
[6]	CHEN Yong-ying, PENG Pan, XU Lei-lei. Application of SVM prediction model in judging the degree of pathological differentiation of primary hliver cancerepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 785-788.
[7]	YANG Ya-meng, LUO Dan-feng. The inhibitory effects of mTOR inhibitor combined with ursodeoxycholic acid on the growth, immune escape, and Ras/ERK signaling pathway of hepatocellular carcinoma in rats [J]. Chinese Hepatolgy, 2023, 28(7): 789-793.
[8]	GUO Dan-dan, QIN Ling, GAO Weng-feng, YUAN Chun-wang, ZHANG Ying-hua, ZHANG Yong-hong. Correlation between the plasma levels of interleukin-33 and hepatocellular carcinoma, thermal ablation therapy [J]. Chinese Hepatolgy, 2023, 28(6): 665-667.
[9]	MA Bo-heng, WANG Xia, WU Ying. An evaluation of serum biochemical indexes, pathological characteristics and surgical treatment efficacy of sarcomatoid hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(6): 676-679.
[10]	JIN Zhi-en, XU pan, YUAN Hong-wei, XU Jing-jiang. A comparison between HCV-related hepatocellular carcinoma patients with or without direct acting antivirals treatment [J]. Chinese Hepatolgy, 2023, 28(6): 680-682.
[11]	QIAN Hou-long, LI Yang, ZHU Xiang, LU Kui. The efficacy and safety of carrilizumab combined with ramvaritinib in the treatment of unresectable hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(4): 452-456.
[12]	ZHU Jia-zuo, ZHAO Ji-guang, CHENG Zhi-yuan. The efficacy and safety of different doses of apatinib combined with carelizumab in the treatment of advanced liver cancer [J]. Chinese Hepatolgy, 2023, 28(4): 457-460.
[13]	HU Bo-bin, WANG Rong-ming, LIANG Heng-kai, WEI Lu, LI Qing-mei, SU Tu-mei, YIN Qian-bing, JIANG Jian-ning. Expression of ESPL1 gene in hepatocellular carcinoma tissue and its role in the prognosis assessment [J]. Chinese Hepatolgy, 2023, 28(3): 285-289.
[14]	LI Peng, WANG Wei-wei, CAI Jian-ming, DONG Jing-hui. Consistency analysis of major signs of small liver cancer LI-RADS (2018 edition) [J]. Chinese Hepatolgy, 2023, 28(3): 293-295.
[15]	SU Pei-hua, WEI Meng-ping, ZHAO Cai-yan. Influence on chronic hepatitis B combined with nonalcoholic fatty liver disease on the development of hepatocellular carcinoma and all-cause mortality: A meta-analysis [J]. Chinese Hepatolgy, 2023, 28(3): 299-304.